HomeCompareABMD vs SPHD

ABMD vs SPHD: Dividend Comparison 2026

ABMD yields 0.52% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHD wins by $6.1K in total portfolio value
10 years
ABMD
ABMD
● Live price
0.52%
Share price
$381.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.4K
Annual income
$54.31
Full ABMD calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — ABMD vs SPHD

📍 SPHD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABMDSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABMD + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABMD pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABMD
Annual income on $10K today (after 15% tax)
$44.62/yr
After 10yr DRIP, annual income (after tax)
$46.16/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, SPHD beats the other by $439.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABMD + SPHD for your $10,000?

ABMD: 50%SPHD: 50%
100% SPHD50/50100% ABMD
Portfolio after 10yr
$23.5K
Annual income
$312.82/yr
Blended yield
1.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABMD right now

ABMD
Analyst Ratings
8
Buy
10
Hold
Consensus: Hold
Altman Z
68.8
Piotroski
5/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABMD buys
0
SPHD buys
0
No recent congressional trades found for ABMD or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABMDSPHD
Forward yield0.52%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$20.4K$26.5K
Annual income after 10y$54.31$571.32
Total dividends collected$535.00$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ABMD vs SPHD ($10,000, DRIP)

YearABMD PortfolioABMD Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$10,752$52.49$11,133$432.85$381.00SPHD
2$11,558$52.75$12,363$450.36$805.00SPHD
3$12,420$52.99$13,695$467.39$1.3KSPHD
4$13,343$53.22$15,138$483.90$1.8KSPHD
5$14,330$53.43$16,697$499.88$2.4KSPHD
6$15,387$53.63$18,382$515.31$3.0KSPHD
7$16,518$53.82$20,198$530.17$3.7KSPHD
8$17,728$53.99$22,157$544.46$4.4KSPHD
9$19,023$54.16$24,266$558.18$5.2KSPHD
10$20,409$54.31$26,536$571.32$6.1KSPHD

ABMD vs SPHD: Complete Analysis 2026

ABMDStock

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Full ABMD Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this ABMD vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABMD vs SCHDABMD vs JEPIABMD vs OABMD vs KOABMD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.